The spread, treatment, and prevention of HIV-1: Evolution of a global pandemic

Journal of Clinical Investigation

Volumn 118, Issue 4, 2008, Pages 1244-1254

  Cohen, Myron S ^a   Hellmann, Nick ^b   Levy, Jay A ^c   Decock, Kevin ^d   Lange, Joep ^e  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b BILL AND MELINDA GATES FOUNDATION   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CELLULOSE SULFATE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; NONOXINOL 9; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

AFRICA; CIRCUMCISION; DRUG EFFICACY; DRUG WITHDRAWAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST PATHOGEN INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; LIPODYSTROPHY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEXUALLY TRANSMITTED DISEASE; SURVIVAL; VIRUS TRANSMISSION;

ANIMALS; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE OUTBREAKS; GENOME, VIRAL; HIV INFECTIONS; HIV-1; HUMANS;

EID: 41849127131     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI34706     Document Type: Review

References (148)

1. Centers for Disease Control. 1981. Pneumocystis pneumonia - Los Angeles. MMWR Morb. Mortal. Wkly. Rep. 30:250-252.
2. UNAIDS. 2005. AIDS epidemic update: December 2005. UNAIDS and WHO. Geneva, Switzerland. http://www.unaids.org/epi/2005/doc/EPIupdate2005_pdf_en/ epi-update2005_en.pdf.
3. UNAIDS. 2007. AIDS epidemic update: December 2007. http://www.unaids.org/ en/KnowledgeCentre/HIVData/EpiUpdate/EpiUpdArchive/2007/default.asp.
4. Schneider, E., Glynn, M.K., Kajese, T., McKenna, M.T. 2006. Epidemiology HIV/AIDS - United States, 1981-2005. MMWR Morb. Mortal. Wkly. Rep. 55:589-592.
5. Hahn, B.H., Shaw, G.M., De Cock, K.M., and Sharp, P.M. 2000. AIDS as a zoonosis: scientific and public health implications. Science. 287:607-614.
6. Sharp, P.M., Shaw, G.M., and Hahn, B.H. 2005. Simian immunodeficiency virus infection of chimpanzees. J. Virol. 79:3891-3902.
7. Lemey, P., et al. 2003. Tracing the origin and history of the HIV-2 epidemic. Proc. Natl. Acad. Sci. U. S. A. 100:6588-6592.
8. McCutchan, F.E. 2000. Understanding the genetic diversity of HIV-1. AIDS. 14(Suppl. 3):S31-S44.
9. Jaffar, S., Grant, A.D., Whitworth, J., Smith, P.G., and Whittle, H. 2004. The natural history of HIV-1 and HIV-2 infections in adults in Africa: a literature review [erratum 2004, 82:571]. Bull. World Health Organ. 82:462-469.
10. Damond, F., et al. 2004. Identification of a highly divergent HIV type 2 and proposal for a change in HIV type 2 classification. AIDS Res. Hum. Retroviruses. 20:666-672.
11. Mofenson, L., et al. 2006. Achievements in public health. Reduction in perinatal transmission of HIV infection - United States, 1985-2005. MMWR Morb. Mortal. Wkly. Rep. 55:592-597.
12. UNAIDS/World Health Organization. 2006. UNAIDS/WHO epidemiological fact sheets on HIV/AIDS and sexually transmitted diseases, 2006 update. WHO. Geneva, Switzerland. http://www.who.int/hiv/pub/epidemiology/pubfacts/en/.
13. Galvin, S.R., and Cohen, M.S. 2004. Sexual transmission of HIV. Nat. Rev. Microbiol. 2:33-42.
14. Levy, J.A. 1988. The transmission of AIDS: the case of the infected cell. JAMA. 259:3037-3038.
15. Pilcher, C.D., et al. 2007. Amplified transmission of HIV-1: comparison of HIV-1 concentrations in blood and semen in acute and chronic infection. AIDS. 21:1723-1730.
16. Pilcher, C.D., Eron, J.J., Jr., Galvin, S., Gay, C., and Cohen, M.S. 2004. Acute HIV revisited: new opportunities for treatment and prevention. J. Clin. Invest. 113:937-945.
17. Stacey, A., et al. 2007. Elevations in plasma levels of innate cytokines prior to the peak in plasma viremia in acute HIV-1 infection [abstract]. The Keystone Symposia Global Health Series. HIV vaccines: from basic research to clinical trials (X7). March 25-30. Whistler, British Columbia, Canada.
18. Wawer, M.J., et al. 2005. HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J. Infect. Dis. 191:1403-1409.
19. Pilcher, C.D., et al. 2004. brief but efficient: acute HIV infection and the sexual transmission of HIV. J. Infect. Dis. 189:1785-1792.
20. Fellay, J., et al. 2007. A whole-genome association study of major determinants for host control of HIV-1. Science. 317:944-947.
21. Abu-Raddad, L.J., Patnaik, P., and Kublin, J.G. 2006. Dual infection with HIV and malaria fuels the spread of both diseases in sub-Saharan Africa [erratum 2007, 315:598]. Science. 314:1603-1606.
22. Quinn, T.C., et al. 2000. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N. Engl. J. Med. 342:921-929.
23. Fideli, U.S., et al. 2001. Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. AIDS Res. Hum. Retroviruses. 17:901-910.
24. Chakraborty, H., et al. 2001. Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model. AIDS. 15:621-627.
25. Fleming, D.T., and Wasserheit, J.N. 1999. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex. Transm. Infect. 75:3-17.
26. Grosskurth, H., et al. 1995. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomized controlled trial. Lancet. 346:530-536.
27. Freeman, E.E., et al. 2006. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS. 20:73-83.
28. Brass, A.L., et al. 2008. Identification of host proteins required for HIV infection through a functional genomic screen. Science. 319:921-926.
29. Long, E.M., et al. 2000. Gender differences in HIV-1 diversity at time of infection. Nat. Med. 6:71-75.
30. Levy, J.A. 1996. Infection by human immunodeficiency virus - CD4 is not enough. N. Engl. J. Med. 335:1528-1530.
31. Berger, E.A., Murphy, P.M., and Farber, J.M., 1999. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17:657-700.
32. Moore, J.P., Kitchen, S.G., Pugach, P., and Zack, J.A. 2004. The CCR5 and CXCR4 coreceptors - central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res. Hum. Retroviruses. 20:111-126.
33. Liu, R., et al. 1996. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 86:367-377.
34. Gonzalez, E., et al. 2005. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science. 307:1434-1440.
35. Taha, T.E., et al. 1998. Bacterial vaginosis and disturbances of vaginal flora: association with increased acquisition of HIV. AIDS. 12:1699-1706.
36. Donoval, B.A., et al. 2006. HIV-1 target cells in foreskins of African men with varying histories of sexually transmitted infections. Am. J. Clin. Pathol. 125:386-391.
37. Rowland-Jones, S.L., et al. 1998. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J. Clin. Invest. 102:1758-1765.
38. Kaul, R., et al. 1999. HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers. AIDS. 13:23-29.
39. Stranford, S., et al. 1999. Lack of infection in HIV-exposed individuals is associated with a strong CD8+ cell noncytotoxic anti-HIV response. Proc. Natl. Acad. Sci. U. S. A. 96:1030-1035.
40. Piantadosi, A., Chohan, B., Chohan, V., McClelland, R.S., and Overbaugh, J. 2007. Chronic HIV-1 infection frequently fails to protect against superinfection. PLoS Pathog. 3:e177.
41. Letvin, N.L., et al. 2006. Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science. 312:1530-1533.
42. Robertson, D.L., et al. 2000. HIV-1 nomenclature proposal. Science. 288:55-56.
43. Baeten, J.M., et al. 2007. HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J. Infect. Dis. 195:1177-1180.
44. Ping, L.H., et al. 1999. Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: underrepresentation of X4 variants. J. Virol. 73:6271-6281.
45. Siliciano, J.D., and Siliciano, R.F. 2000. Latency and viral persistence in HIV-1 infection. J. Clin. Invest. 106:823-825.
46. Levy, J.A. 2003. The search for the CD8+ cell anti-HIV factor (CAF). Trends in Immunol. 24:628-632.
47. Cheng-Mayer, C., Seto, D., Tateno, M. and Levy, J.A. 1988. Biologic features of HIV that correlate with virulence in the host. Science. 240:80-82.
48. Connor, R.I., Sheridan, K.E., Ceradini, D., Choe, S., and Landau, N.R. 1997. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J. Exp. Med. 185:621-628.
49. McCune, J.M. 2001. The dynamics of CD4+ T-cell depletion in HIV disease. Nature. 410:974-979.
50. Mehandru, S., et al. 2004. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J. Exp. Med. 200:761-770.
51. Brenchley, J.M., et al. 2004. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J. Exp. Med. 200:749-759.
52. Sheehy, A.M., Gaddis, N.C., Chol, J.D., and Malim, M.H. 2002. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature. 418:646-650.
53. Stremlau, M., et al. 2004. The cytoplasmic body component TRIM5a restricts HIV-1 infection in Old World monkeys. Nature. 427:848-853.
54. Cao, Y., Qin, L., Zhang, L., Safrit, J., and Ho, D.D. 1995. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection N. Engl. J. Med. 332:201-208.
55. Pantaleo, G., et al. 1995. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N. Engl. J. Med. 332:209-216.
56. Deacon, N.J., et al. 1995. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science. 270:988-991.
57. Bansal, A., et al. 2007. Immunological control of chronic HIV-1 infection: HLA-mediated immune function and viral evolution in adolescents. AIDS. 21:2387-2397.
58. Akira, S., Uematsu, S., and Takeuchi, O. 2006. Pathogen recognition and innate immunity. Cell. 124:783-801.
59. Spear, G.T. 1993. Interaction of non-antibody factors with HIV in plasma. AIDS. 7:1149-1157.
60. Piguet, V., and Steinman, R.M. 2007. The interaction of HIV with dendritic cells: outcomes and pathways. Trends Immunol. 28:503-510.
61. Siegal, F.P., et al. 1999. The nature of the principal type 1 interferon-producing cells in human blood. Science. 284:1835-1837.
62. Ito, T., Kanzler, H., Duramad, O., Cao, W., and Liu, Y.J. 2006. Specialization, kinetics, and repertoire of type 1 interferon responses by human plasmacytoid predendritic cells. Blood. 107:2423-2431.
63. Soumelis, V., Scott, I., Gheyas, F., Bouhour, D., Cozon, G., 2001. Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients. Blood. 98:906-912.
64. Schmidt, B., Ashlock, B.M., Foster, H., Fujimura, S., and Levy, J.A. 2005. HIV-infected cells are major inducers of plasmacytoid dendritic cells (PDC) interferon production, maturation and migration. Virology. 343:256-266.
65. Cooper, M.A., Fehniger, T.A., and Caligiuri, M.A. 2001. The biology of human natural killer-cell subsets. Trends Immunol. 22:633-640.
66. Burton, D.R., et al. 2004. HIV vaccine design and the neutralizing antibody protection. Nat. Immunol. 5:233-236.
67. Forthal, D.N., Gilbert, P.B., Landucci, G., and Phan, T. 2007. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J. Immunol. 178:6596-6603.
68. Homsy, J., Meyer, M., and Levy, J.A. 1990. Serum enhancement of human immunodeficiency virus (HIV) correlates with disease in HIV infected individuals. J. Virol. 64:1437-1440.
69. Douek, D.C., et al. 2002. HIV preferentially infects HIV-specific CD4+ T cells. Nature. 417:95-98.
70. Kagi, S., et al. 1995. The role of perforin- and Fas-dependent cytotoxicity in protection against cytopathic and noncytopathic viruses. Eur. J. Immunol. 25:3256-3262.
71. Ogg, G.S., et al. 1998. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science. 279:2103-2106.
72. Haas, G., et al. 1996. Dynamics of viral variants in HIV-1 Nef and specific cytotoxic T lymphocytes in vivo. J. Immunol. 157:4212-4221.
73. Zinkernagel, R.M., and Hengartner, H. 1994. T-cell-mediated immunopathology versus direct cytolysis by virus: implications for HIV and AIDS. Immunol. Today. 15:262-268.
74. Lieberman, J. 2004. Tracking the killers: how should we measure CD8 T cells in HIV infection? AIDS. 18:1489-1493.
75. Palella, F.J., Jr., et al. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338:853-860.
76. Larder, B. 2001. Mechanisms of HIV-1 drug resistance. AIDS. 15(Suppl. 5):S27-S34.
77. Kaufmann, D.E., et al. 2004. Limited durability of viral control following treated acute HIV infection. PLoS Med. 1:e36.
78. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, et al. 2006. CD4+ count-guided interruption of antiretroviral treatment. N. Engl. J. Med. 355:2283-2296.
79. [Anonymous]. 2002. Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach. WHO. Geneva, Switzerland. http://www.who.int/entity/hiv/pub/prev_care/en/arvrevision2003en.pdf.
80. [Anonymous]. 2003. Treating 3 million by 2005: making it happen. WHO. Geneva, Switzerland. ttp://www.who.int/entity/3by5/publications/documents/en/ 3by5StrategyMakingItHappen.pdf.
81. [Anonymous]. 2006. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. WHO. Geneva, Switzerland. http://www.who.int/hiv/pub/guidelines/adult/en/index.html.
82. Ojikutu, B. 2007. Introduction: the realities of antiretroviral therapy rollout: overcoming challenges to successful programmatic implementation. J. Infect. Dis. 196(Suppl. 3):S445-S448.
83. Farmer, P., et al. 2001. Community-based approaches to HIV treatment in resource-poor settings. Lancet. 358:404-409.
84. Marston, B.J., et al. 2007. A program to provide antiretroviral therapy to residents of an urban slum in Nairobi, Kenya. J. Int. Assoc. Physicians AIDS Care (Chic. Ill.). 6:106-112.
85. Braitstein, P., et al. 2006. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 367:817-824.
86. French, M.A., Price, P., and Stone, S.F. 2004. Immune restoration disease after antiretroviral therapy. AIDS 18:1615-1627.
87. Ferradini, L., et al. 2006. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment Lancet. 367:1335-1342.
88. Corbett, E.L., Marston, B., Churchyard, G.J., and De Cock, K.M. 2006. Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral therapy. Lancet. 367:926-937.
89. The Stop TB Partnership. TB/HIV - facts at a glance. http://www.stoptb. org/news/archives/iacxv/assets/InfoPack/InfoPackEnglish.pdf.
90. Bucher, H.C., et al. 1999. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS. 13:501-507.
91. Daley, C.L., et al. 1992. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus: an analysis using restriction-fragment length polymorphisms. N. Engl. J. Med. 326:231-235.
92. Whalen, C.C., et al. 2000. Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda. AIDS. 14:1219-1228.
93. Jones, B.E., et al. 1993. Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am. Rev. Respir. Dis. 148:1292-1297.
94. Lee, W.M. 2003. Drug-induced hepatotoxicity. N. Engl. J. Med. 349:474-485.
95. De Maat, M.M., et al. 2003. Drug interactions between antiretroviral drugs and co-medicated agents. Clin. Pharmacokinet. 42:223-282.
96. van der Valk, M., et al. 2004. Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in HIV-1-infected patients randomly allocated to zidovudine- or stavudine-based therapy. Antivir. Ther. 9:385-393.
97. Newell, M.L., et al. 2004. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet. 364:1236-1243.
98. Puthanakit, T., et al. 2005. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's national access to antiretroviral program. Clin. Infect. Dis. 41:100-107.
99. [Anonymous]. 2007. Antiretroviral therapy for HIV infection in infants and children: towards universal access. WHO. Geneva, Switzerland. http://www.who.int/hiv/pub/guidelines/paediatric020907.pdf.
100. [Anonymous]. 2007. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report. WHO. Geneva, Switzerland. http://www.who.int/hiv/mediacentre/universal_access_progress_report_en.pdf.
101. Cohen, M.S., Gay, C., Kashuba, A.D., Blower, S., and Paxton, L. 2007. Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann. Intern. Med. 146:591-601.
102. Wegbreit, J., Bertozzi, S., DeMaria, L.M., and Padian, N.S. 2006. Effectiveness of HIV prevention strategies in resource-poor countries: tailoring the intervention to the context. AIDS. 20:1217-1235.
103. Global HIV Prevention Working Group. 2007. Bringing HIV prevention to scale: an urgent global priority. http://www.globalhivprevention.org/index.html.
104. Dao, H., et al. 2007. International recommendations on antiretroviral drugs for treatment of HIV-infected women and prevention of mother-to-child HIV transmission in resource-limited settings:2006 update. Am. J. Obstet. Gynecol. 197:S42-S55.
105. Stramer, S.L., et al. 2004. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N. Engl. J. Med. 351:760-768.
106. Underhill, K., Montgomery, P., and Operario, D. 2007. Sexual abstinence only programs to prevent HIV infection in high income countries: systematic review. BMJ. 335:248-259.
107. Des Jarlais, D.C., and Friedman, S.R. 1987. HIV infection among intravenous drug users: epidemiology and risk reduction. AIDS. 1:67-76.
108. Stoneburner, R.L., and Low-Beer, D. 2004. Population-level HIV declines and behavioral risk avoidance in Uganda. Science. 304:714-718.
109. Cohen, M.S. 2007. Preventing sexual transmission of HIV. Clin. Infect. Dis. 45(Suppl. 4):S287-S292.
110. Auvert, B., et al. 2005. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2:e298.
111. Gray, R.H., et al. 2007. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet. 369:657-666.
112. Bailey, R.C., et al. 2007. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 369:643-656.
113. Padian, N.S., et al. 2007. Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet. 370:251-261.
114. Grosskurth, H., et al. 1995. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet. 346:530-536.
115. Kamali, A., et al. 2003. Syndromic management of sexually-transmitted infections and behaviour change interventions on transmission of HIV-1 in rural Uganda: a community randomised trial. Lancet. 361:645-652.
116. Wawer, M.J., et al. 1999. Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Rakai Project Study Group. Lancet. 353:525-535.
117. Korenromp, E.L., et al. 2005. Determinants of the impact of sexually transmitted infection treatment on prevention of HIV infection: a synthesis of evidence from the Mwanza, Rakai, and Masaka intervention trials. J. Infect. Dis. 191(Suppl. 1):S168-S178.
118. Watson-Jones, D., et al. 2007. Impact of HSV-2 suppressive therapy on HIV incidence in HSV-2 seropositive women: a randomised controlled trial in Tanzania. Fourth International AIDS Society Conference on HIV Pathogenesis. Sydney, New South Wales, Australia. Abstract MOAC104.
119. Celum, C., et al. 2008. HSV-2 suppressive therapy for prevention of HIV acquisition: results of HPTN 039 [abstract]. Fifteenth Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts, USA. 15:32LB.
120. Celum, C.L., Robinson, N.J., and Cohen, M.S. 2005. Potential effect of HIV type 1 antiretroviral and herpes simplex virus type 2 antiviral therapy on transmission and acquisition of HIV type 1 infection. J. Infect. Dis. 191(Suppl.):S107-S114.
121. Global HIV/AIDS Vaccine Enterprise. 2005. The Global HIV/AIDS Vaccine Enterprise: scientific strategic plan. PLoS Med. 2:e25.
122. Johnston, M.I., and Fauci, A.S. 2007. An HIV vaccine - evolving concepts. N. Engl. J. Med. 356:2073-2081.
123. Montefiori, D., et al. 2007. Antibody-based HIV-1 vaccines: recent developments and future directions. PLoS Med. 4:e348.
124. Flynn, N.M., et al. 2005. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191:654-665.
125. Cohen, J. 2007. Did Merck's failed HIV vaccine cause harm? Science. 318:1048-1049.
126. Roddy, R.E., et al. 1998. A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N. Engl. J. Med. 339:504-510.
127. Van Damme, L., et al. 2002. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet. 360:971-977.
128. Ramjee, G., Govinden, R., Morar, N.S., and Mbewu, A. 2007. South Africa's experience of the closure of the cellulose sulphate microbicide trial. PLoS Med. 4:e235.
129. Feldblum, P.J., et al. 2008. SAVVY Vaginal Gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PloS ONE. 3:e474.
130. García-Lerma, J.G., et al. 2008. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PloS Med. 5:e28.
131. Cohen, M.S., and Kashuba, A. 2008. Antiretroviral therapy for prevention of HIV infection: new clues from an animal model. PLoS Med. 5:e30.
132. Peterson, L., et al. 2007. Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin. Trials. 2:e27.
133. Grant, R.M., et al. 2005. AIDS: promote HIV chemoprophylaxis research, don't prevent it. Science. 309:2170-2171.
134. Singh, J.A., and Mills, E.J. 2005. The abandoned trials of pre-exposure prophylaxis for HIV: what went wrong? PLoS Med. 2:e234.
135. Cooper, E.R., et al. 2002. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J. Acquir. Immune Defic. Syndr. 29:484-494.
136. Luo, C., et al. 2007. Global progress in PMTCT and paediatric HIV care and treatment in low- and middle-income countries in 2004-2005. Reprod. Health Matters. 15:179-189.
137. Reynolds, H.W., Janowitz, B., Homan, R., and Johnson, L. 2006. The value of contraception to prevent perinatal HIV transmission. Sex. Transm. Dis. 33:350-356.
138. Guay, L.A., et al. 1999. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 354:795-802.
139. Jackson, J.B., et al. 2001. Identification of K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS. 14:F111-F115.
140. Eshleman, S.H., et al. 2001. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS. 15:1951-1957.
141. Jourdain, G., et al. 2004. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N. Engl. J. Med. 351:229-240.
142. McIntyre, J. 2005. Controversies in the use of nevirapine for the prevention of mother-to-child transmission of HIV [abstract]. Conference on Retroviruses and Opportunistic Infections. 12:8.
143. Bunnell, R., et al. 2006. Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS. 20:85-92.
144. Fraser, C., Hollingsworth, T.D., Chapman, R., de Wolf, F., and Hanage, W.P. 2007. Variation in HIV-1 set-point viral load: epidemiological analysis and an evolutionary hypothesis. Proc. Natl. Acad. Sci. U. S. A. 104:17441-17446.
145. The Associated Press. 31 Jan 2008. Swiss change safe sex message on HIV. USA Today. http://www.usatoday.com/news/world/2008-01-31-switzerland- aids_N.htm.
146. Levy, J.A. 2007. HIV and the pathogenesis of AIDS. 3rd edition. ASM Press. Washington, DC, USA. 588 pp.
147. Salomon, J.A., et al. 2005. Integrating HIV prevention and treatment: from slogans to impact. PloS Med. 2:e16.
148. Stover, J., et al. 2006. The global impact of scaling up HIV/AIDS prevention programs in low- and middle-income countries. Science. 311:1474-1476.